Back to results
US 12,285,498 B2Granted
Pharmaceutical composition with nanoparticle-based drug delivery combined with non-invasive radiographic monitoring model
AssigneeNanomedtrix, LLC
InventorsJoe G Assouline, Sean K. Sweeney
Life of this patent
Estimating the term…
Abstract
A mesoporous silica nanoparticle (“MSN”); a bioactive agent loaded into the MSN and an enteric coating encapsulating the surface of the MSN for oral administration or combination with more than one other pharmaceutical composition each having distinct bioactive agents.
Claims17
A method of treatment of a tumor comprising the steps of:
- administering to a patient a first pharmaceutical composition and a second pharmaceutical composition;
- wherein the first pharmaceutical composition comprises a mesoporous silica nanoparticle (“MSN”), a first bioactive agent comprising a first chemotherapeutic agent loaded into the MSN, a first coating encapsulating the surface of the MSN, and a targeting peptide or an amino acid covalently linked to the MSN;
- wherein the second pharmaceutical composition comprises an MSN, a second bioactive agent comprising a second chemotherapeutic agent loaded into the MSN, a second coating encapsulating the MSN, and a targeting peptide or an amino acid covalently linked to the MSN;
- and
- wherein the first bioactive agent is distinct from the second bioactive agent and the first chemotherapeutic agent and the second chemotherapeutic agent are chemically incompatible such that interaction between the two results in a reduction in effectiveness;
- and wherein the first pharmaceutical composition comprising the first chemotherapeutic agent and the second pharmaceutical composition comprising the second chemotherapeutic agent act upon a tumor sequentially or substantially concurrently without chemically interacting with each other.
3 more elements
A method of treatment bladder cancer comprising the steps of:
- administering intravesically to a bladder of a patient a first pharmaceutical composition comprising of a mesoporous silica nanoparticle (“MSN”), a first bioactive agent loaded into the MSN, a first coating encapsulating the surface of the MSN, and a targeting peptide or an amino acid covalently linked to the MSN;
- administering orally to the patient and concurrently with the intravesicular administration of the first pharmaceutical composition to the bladder of the patient a second pharmaceutical composition comprising an MSN, a second bioactive agent loaded into the MSN, a second coating encapsulating the MSN, and a targeting peptide or an amino acid covalently linked to the MSN;
- and
- wherein the first bioactive agent is distinct from and chemically incompatible with the second bioactive agent;
- and wherein the first pharmaceutical composition and the second pharmaceutical composition act upon a tumor sequentially or substantially concurrently without chemically interacting with each other.
2 more elements
Dependencies are inferred from the claim text.